| http://www.w3.org/ns/prov#value | - Within our Global Generics business, we invested in product development and an additional bio studies to support further expansion of our product portfolios, including patch and gel products such as our recently announced first-to-file generic version of Daytrana, a transdermal patch to treat ADHD. In our Global Brands business, we are on target to initiate our Esmya Phase III uterine fibroid stud
|
